BTK and Alzheimer disease: PRN473, a covalent BTK inhibitor in topical form applied in multiple topical doses for 42 days, was evaluated versus placebo in 39 adult (18 to 70 years of age) patients with mild to moderate AD in a Phase 2a randomized, intra-patient, double-blind, placebo-controlled study.